1) Strong Q1 Performance and Strategic Divestiture
- Revvity reported a 3% total company organic growth in Q1 2026, exceeding expectations.
- Adjusted operating margins were 23.6%, surpassing the 23% outlook.
- Adjusted earnings per share (EPS) reached $1.06, above the guidance range of $1.02 to $1.04.
- The company plans to divest its immunodiagnostics business in China, which accounted for 6% of total revenue last year, to focus on higher-return opportunities.
- The divestiture is expected to improve 2026 organic growth by approximately 100 basis points and enhance operating margins by 30 basis points.

2) Financial Guidance and Segment Results
- For 2026, Revvity expects pro forma organic growth of 3% to 4%, with adjusted operating margins projected at 28.4% and adjusted EPS between $5.20 to $5.30.
- The company generated $711 million in revenue for Q1, with 3% organic growth and a 3% tailwind from FX.
- Life Sciences segment revenue was $362 million (up 3% organic), while Diagnostics generated $349 million (up 4% organic).
- The pro forma revenue for Q1, excluding the immunodiagnostics business, was $687 million, reflecting a 6% organic growth.

3) Market Trends and Operational Insights
- The pharma and biotech spending environment showed modest improvement, with low single-digit growth in Q1.
- Reagents and instruments sales to pharma/biotech customers grew in the low single digits, marking the strongest growth since Q2 2023.
- The reproductive health business grew in the low double digits, driven by strong performance in newborn screening and contributions from the Genomics England contract.
- Revvity continues to innovate with new software offerings, including Xynthetica and BioDesign, aimed at enhancing AI-driven research capabilities.

4) AI Strategy and Internal Efficiency Initiatives
- Revvity is leveraging AI to transform both its product offerings and internal operations, with a structured approach leading to higher employee adoption rates.
- The company expects significant margin expansion from ongoing cost efficiency initiatives, with full implementation anticipated by mid-2026.
- The internal AI deployment is expected to yield remarkable cost-out impacts, enhancing productivity and operational efficiency.

5) Investor Outlook and Missing Elements
- The company is optimistic about future growth, particularly in Life Sciences and Diagnostics, but remains cautious due to potential market volatility.
- There was no specific guidance provided for 2027, but management indicated that the benefits of cost initiatives would start to materialize in the first half of that year.
- The call did not cover detailed projections for the impact of the divestiture on future cash flows or specific M&A strategies beyond tuck-ins.

Bottom line: Revvity's strategic divestiture of its immunodiagnostics business in China is expected to streamline operations and enhance financial performance, positioning the company for improved organic growth and margins in 2026 and beyond. The focus on innovation and AI integration further supports a positive outlook for shareholders.